IRIDEX Co.

IRIDEX reported a Q2/2026 loss of $0.07 per share on revenue of $12.6 million, missing analyst expectations of −$0.02 and $14.13 million. The retina segment weakened markedly, while the glaucoma business with Cyclo G6 probes grew strongly in volume and revenue (probes +35%, product revenue +19%). A milestone was highlighted: the company generated positive operating cash flow for the first time thanks to tighter cost control and improved working capital. IRIDEX confirmed its full-year revenue guidance of $51–53 million; the stock showed slight after‑hours declines despite the positive cash‑flow news. » More on de.investing.com

Iridex has agreed with the US purchasing group EyeProGPO on preferred terms for its PASCAL laser platform, the Laser IQ 532/577 and the OcuLight‑TX for more than 1,800 members. The agreement expands an existing collaboration that already covers Cyclo‑G6 lasers and glaucoma probes, broadening the product range available to EyeProGPO members. Iridex has a market capitalization of $17.91 million and 12‑month revenue of $52.67 million; analysts currently view the stock as undervalued, with a price target of $2.75 according to InvestingPro. » More on de.investing.com

IRIDEX reported Q4 2025 revenue of $14.7m (+16% year‑on‑year) and earnings per share of -$0.01, better than the -$0.02 forecast. Net loss fell to $0.2m from $0.8m a year earlier, operating expenses were reduced and the company generated positive cash flow in the quarter. Drivers were strong product sales of the Cyclo G6 and PASCAL systems; adjusted EBITDA was positive again for the first time. Management expects further revenue growth in 2026, adjusted operating expenses of $19.0–19.5m and improved gross margins through outsourcing of manufacturing. » More on de.investing.com

Iridex has signed a 90‑month triple‑net lease for about 30,784 square feet of office space in San Jose, expected to begin on July 1, 2026, with an optional 60‑month extension. Rent is free for the first six months after move‑in; minimum rent in the first full year is about $646,464 and rises roughly 3% annually. The relocation is expected to yield annual cost savings of about $0.6 million after implementation. Iridex also reported preliminary Q4 revenue of $14.6–14.8 million, positive cash flow, and expects adjusted positive EBITDA for 2025. » More on de.investing.com

An independent study published in Ophthalmology and Therapy at the Maastricht University Eye Clinic shows that retreatment with Iridex's MicroPulse transscleral laser reduced intraocular pressure in 76 treated eyes by about 25–35% three months after retreatment, regardless of response to the initial treatment. Intervals until retreatment varied widely (in non-responders already after four months, with late loss of effect up to 28 months), and repeat treatments were possible. Despite revenue of $50.65 million, Iridex continues to post losses; in Q3 2025 the company reported a net loss of $1.6 million and missed revenue and earnings forecasts. » More on de.investing.com